Rockefeller Capital Management
ALDX icon

Rockefeller Capital Management’s Aldeyra Therapeutics ALDX Stock Holding History

Rockefeller Capital Management’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-38
Closed – – 2025
2022
Q4 		$0 Hold
38
– – ﹤0.01% 3822
2022
Q3 		$0 Hold
38
– – ﹤0.01% 3847
2022
Q2 		$0 Hold
38
– – ﹤0.01% 4078
2022
Q1 		$0 Hold
38
– – ﹤0.01% 3844
2021
Q4 		$0 Buy
+38
New +$290 ﹤0.01% 3742
2021
Q3 		– Sell
-39
Closed – – 3670
2021
Q2 		$0 Buy
+39
New +$469 ﹤0.01% 3424

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Rockefeller Capital Management's ALDX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Aldeyra Therapeutics (ALDX) in Q1 2023, closing a stake of 38 shares.

Rockefeller Capital Management first reported a position in ALDX in Q2 2021 and held it in 6 quarters. The position peaked at $0 in Q4 2022. 108 funds tracked by Wall St. Rank hold ALDX as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Aldeyra Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 38 Aldeyra Therapeutics shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in Aldeyra Therapeutics in Q2 2021 and held it in 6 quarters.
  • Rockefeller Capital Management's Aldeyra Therapeutics position peaked at $0 in Q4 2022.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.